Track market-moving stories before they get noisy

NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, Sept.

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.

Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.

It also includes access to the Zacks Style Scores.

What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.

Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.

Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.

Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.

VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.

How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.

Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.8% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.

That's where the Style Scores come in.

To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.

Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.

Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Labcorp Holdings (LH - Free Report) Headquartered in Burlington, NC, Labcorp Holdings, Inc. (Labcorp) is a leading healthcare diagnostics company, providing comprehensive clinical laboratory services and end-to-end drug development support. In 2015, Labcorp acquired New Jersey-based Covance, a drug development services company providing a wide range of early stage and late-stage product development services on a worldwide basis primarily to the pharmaceutical and biotechnology industries.

LH is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.

It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 17.84; value investors should take notice.

Eight analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.32 to $18.32 per share. LH also boasts an average earnings surprise of +3.1%.

With a solid Zacks Rank and top-tier Value and VGM Style Scores, LH should be on investors' short list.

Enhanced digital experience designed to improve visibility, simplify workflows and support faster decision-making

, /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory solutions, today announced enhancements to the digital experience of Labcorp Global Trial Connect™, the company's portfolio of clinical trial services, data and technology that enhances and accelerates delivery. The newly redesigned platform introduces new capabilities across the Labcorp Sponsor™ and Labcorp Investigator™ portal experiences of Global Trial Connect, providing greater visibility across studies, simplifying workflows and helping sponsors and investigator sites make faster, more informed decisions.

Labcorp Global Trial Connect "As clinical trials become increasingly complex, sponsors and investigator sites need technology that helps them work more effectively," said Brian Caveney, M.D., EVP and president, Biopharma Laboratory Services and chief medical and scientific officer, Labcorp. "The latest enhancements to Global Trial Connect make it easier to access insights, manage study activities and navigate trial complexity with confidence, allowing customers to focus less on operational tasks and more on advancing research and supporting patients."

Designed with Customers, for Customers
Guided by input from more than 80 sponsors and 100 investigator sites worldwide, the latest enhancements to Global Trial Connect were informed by extensive customer feedback, product testing and direct input. Key updates include:

A more intuitive user experience with simplified navigation and role-based customization Streamlined study management with integrated tools for study oversight, reporting and supply tracking Embedded in-portal kit ordering that reduces manual data entry by 75% while optimizing inventory oversight and management Greater visibility into study performance through a unified Study Oversight Dashboard that brings together study, site, sample and supply insights in a single view Simplified report creation with a new Report Wizard that guides users through building and customizing reports to meet their needs Enhanced sample visibility through end-to-end tracking across the sample lifecycle Advancing the Future of Clinical Trial Delivery
These enhancements represent the latest milestone in Labcorp's ongoing investment in digital solutions across its Biopharma Laboratory Services business, helping sponsors and investigator sites deliver high-quality clinical trials more efficiently. Through continued collaboration with customers, Labcorp will further evolve Global Trial Connect to address emerging industry challenges and provide a more connected experience across the clinical trial lifecycle.

To learn more about the latest capabilities and watch an overview video of the enhancements, visit the Global Trial Connect page https://www.labcorp.com/biopharma/central-labs/global-trial-connect.

About Labcorp 
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests for patients around the world. Learn more at www.labcorp.com. 

SOURCE Labcorp

BURLINGTON, N.C., Aug. 28, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that members of the executive management team will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, Sept.

Collaboration will support leadership development, practice improvement and innovation across the nation's Community Health Centers BURLINGTON, N.C. and BETHESDA, Md.

BURLINGTON, N.C., Aug. 17, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced it will host an Investor Day on Thursday, September 10, 2026, from 9 a.m.

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.

The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.

It also includes access to the Zacks Style Scores.

What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.

Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.

Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.

Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.

VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.

How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.

Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.94% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.

That's where the Style Scores come in.

You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only has a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.

Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.

Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Labcorp Holdings (LH - Free Report) Headquartered in Burlington, NC, Labcorp Holdings, Inc. or Labcorp, is a leading healthcare diagnostics company, providing comprehensive clinical laboratory services and end-to-end drug development support. In 2015, Labcorp acquired NJ based Covance, a drug development services company providing a wide range of early stage and late-stage product development services on a worldwide basis primarily to the pharmaceutical and biotechnology industries.

LH is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.

Momentum investors should take note of this Medical stock. LH has a Momentum Style Score of A, and shares are up 15.3% over the past four weeks.

Six analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.24 to $18.24 per share. LH also boasts an average earnings surprise of +3.1%.

With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, LH should be on investors' short list.

Labcorp's FDA‑approved PGDx elio® tissue complete CDx helps identify advanced melanoma patients with certain BRAF variants eligible for BRAF and BRAF/MEK inhibitor therapies Supports access to targeted treatment options for the deadliest form of skin cancer , /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced that the U.S. Food and Drug Administration (FDA) has approved Labcorp's PGDx elio® tissue complete CDx as a companion diagnostic to help identify patients with advanced melanoma with certain BRAF variants who may benefit from treatment with FDA-approved targeted therapiesi.

Addressing a Critical Need in Advanced Melanoma
Melanoma is the deadliest form of skin cancer, with a five‑year survival rate of just 16% for patients diagnosed with stage IV disease. However, targeted therapies are an important treatment option for patients with advanced melanoma whose tumors have a BRAF alteration. As a companion diagnostic, PGDx elio tissue complete CDx helps clinicians identify which melanoma patients carry these BRAF V600E/K variants and may benefit from treatment with FDA-approved BRAF inhibitors and BRAF/MEK inhibitor combination regimens.

"Advanced melanoma is an extremely aggressive and life‑threatening cancer, but targeted treatments are offering real hope for patients," said Shakti Ramkissoon, M.D., Ph.D., vice president, medical lead for oncology at Labcorp. "Labcorp's FDA‑approved companion diagnostic improves access to these therapies by allowing clinicians to confirm which patients may be eligible for and can start receiving those treatments as soon as possible."

A Comprehensive and Scalable Testing Solution
Labcorp's PGDx elio tissue complete CDx is approved for use by qualified healthcare professionals across hospitals and clinical laboratories, supporting broader patient access to high-quality molecular testing. As a kit-based solution, the companion diagnostic can be implemented directly within hospitals and health systems, expanding access to testing while enabling organizations to retain samples and data that may inform future clinical research.

The addition of Labcorp's PGDx elio tissue complete CDx reflects the continued expansion of Labcorp's precision medicine portfolio, which includes comprehensive tissue- and liquid-based oncology diagnostics designed to support personalized care. For more information about PGDx elio tissue complete or Labcorp's oncology solutions, visit https://www.labcorp.com/oncology/providers/testing-solutions/kitted-solutions/pgdx-elio-tissue-complete-cdx.

About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests for patients around the world. Learn more at www.labcorp.com.

iPGDx elio tissue complete CDx is a qualitative next generation sequencing-based in vitro diagnostic device that uses a high-throughput hybridization-based capture technology utilizing DNA isolated from formalin-fixed paraffin embedded tumor tissue. The PGDx elio tissue complete CDx targeted panel can detect single nucleotide variants, small insertions and deletions, copy number amplifications, and translocations. It is intended to be used as a companion diagnostic to identify melanoma patients who may benefit from treatment with targeted therapies listed below in accordance with the approved therapeutic product labeling.

PGDx elio tissue complete CDx Indications
Indication: Melanoma
Biomarker: BRAF V600E/ BRAF V600K
Therapy: BRAF inhibitors approved by FDA or BRAF/MEK inhibitor combinations approved by FDA

SOURCE Labcorp

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.

Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.

Zacks Premium includes access to the Zacks Style Scores as well.

What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.

Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.

Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.

Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.

VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.

How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.

Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.94% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.

That's where the Style Scores come in.

To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.

As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.

For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Labcorp Holdings (LH - Free Report) Headquartered in Burlington, NC, Labcorp Holdings, Inc. or Labcorp, is a leading healthcare diagnostics company, providing comprehensive clinical laboratory services and end-to-end drug development support. In 2015, Labcorp acquired NJ based Covance, a drug development services company providing a wide range of early stage and late-stage product development services on a worldwide basis primarily to the pharmaceutical and biotechnology industries.

LH is a #2 (Buy) on the Zacks Rank, with a VGM Score of B.

It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 16.89; value investors should take notice.

For fiscal 2026, five analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.20 to $18.20 per share. LH boasts an average earnings surprise of +3.1%.

With a solid Zacks Rank and top-tier Value and VGM Style Scores, LH should be on investors' short list.

L3Harris’ Record Backlog Makes Its Stock Sell-Off Look OverdoneLabcorp NYSE: LH reported second-quarter 2026 revenue growth, margin expansion and higher adjusted earnings, prompting the laboratory services company to raise the midpoint of its full-year revenue and adjusted EPS guidance.

Revenue rose 5.8% year over year to $3.7 billion, while adjusted operating margin expanded 70 basis points to 15.8%, according to Chairman and Chief Executive Officer Adam Schechter. Adjusted earnings per share increased 14.9% to $4.99, and free cash flow was $314 million.

Get Labcorp alerts:

After 15% L3Harris Price Drop, Is It Time to Buy or Time to Fly?“Labcorp delivered another very strong quarter, driven by solid revenue growth, margin expansion, and progress across our strategic priorities,” Schechter said on the company’s earnings call.

Diagnostics Growth and Specialty Testing The Diagnostics segment generated $2.9 billion in revenue, up 5.5% from a year earlier. Organic revenue grew 3.6%, including 1.8% accession volume growth and 1.8% favorable price mix, while acquisitions contributed 1.9% growth. Segment adjusted operating income rose to $523 million, and adjusted operating margin increased 50 basis points to 18%.

Why This Defense ETF Could Keep Rallying as the Iran Conflict EscalatesSchechter said the company’s specialty testing areas—oncology, neurology, autoimmune disease and women’s health—collectively posted double-digit revenue growth in the first half. He said specialty testing also contributes to higher tests per accession, as patients with complex conditions such as cancer may require multiple types of laboratory testing over time.

During the quarter, Labcorp launched ColoSense nationwide, an FDA-approved RNA-based colorectal cancer screening test with at-home collection. Schechter said the test has Medicare coverage and expanding commercial payer access. The company also expanded its cancer-testing offerings with a clinical trial collaboration with Fox Chase Cancer Center involving its PlasmaDetect genome MRD test for non-small cell lung cancer recurrence, as well as broader access to a Roche companion diagnostic for prostate cancer.

Labcorp also cited expanded access to its myOLARIS-KTdx kidney-transplant surveillance test and said its NASHnext blood-based liver-disease test is scheduled to receive Medicare coverage beginning in mid-August.

On reimbursement and collection trends, Chief Financial Officer Julia Wang said Labcorp continues to assume a 30-basis-point full-year impact to Diagnostics volume from Affordable Care Act-related changes. The affected payer cohort represents less than 4% to 5% of total Diagnostics volume, she said. The second quarter saw a 20- to 30-basis-point headwind to Diagnostics volume from this source.

Wang also said Diagnostics bad debt remained in line with prior-year and historical levels, at less than or around 5% of revenue. Schechter noted that growth in Labcorp OnDemand, where consumers pay upfront for testing, is included in patient-pay revenue and does not increase bad debt.

Biopharma Segment Shows Improved Momentum Biopharma Laboratory Services, or BLS, revenue rose 6.5% to $836 million. On an organic constant-currency basis, Central Laboratory Services revenue grew 7.6%, while Early Development revenue increased 2.7%.

BLS adjusted operating income increased to $142 million, or 17% of segment revenue, from $123 million, or 15.7%, a year earlier. Wang attributed the 130-basis-point margin improvement to organic growth and operating efficiencies from strategic actions in the Early Development business. She said those actions have all been announced and are largely complete.

Schechter said Central Laboratory Services represents about 70% of the BLS segment and remains the primary driver of segment growth. He added that Early Development has seen strong request-for-proposal activity, consistent win rates and study starts occurring more on time than in prior periods.

The BLS segment ended the quarter with an $8.7 billion backlog, with approximately $2.7 billion expected to convert into revenue over the next 12 months. Quarterly book-to-bill was 1.14, bringing the trailing 12-month figure to 1.03.

Capital Deployment and Raised Outlook Labcorp deployed capital through acquisitions, share repurchases and dividends during the quarter. The company invested $226 million in acquisitions, repurchased $354 million of shares and paid $59 million in dividends. After retiring $500 million in senior notes, it ended the quarter with $142 million in cash and $5.9 billion in total debt.

In July, the board increased the company’s share-repurchase authorization by $1 billion, bringing the remaining authorization to $1.4 billion.

For 2026, Labcorp now expects enterprise revenue growth of 5.4% to 6.3%, raising the midpoint by 30 basis points. Diagnostics revenue is projected to grow 5.3% to 6%, a 20-basis-point midpoint increase, while BLS revenue is expected to rise 5.5% to 6.5%, with the midpoint raised by 140 basis points.

Adjusted EPS guidance was raised and narrowed to $18.10 to $18.55, implying growth of more than 11% at the midpoint. Full-year free-cash-flow guidance was maintained at $1.24 billion to $1.36 billion. The company continues to expect capital expenditures of about 4% of revenue. Labcorp expects both Diagnostics and BLS margins to improve in 2026, with BLS margin expansion exceeding that of Diagnostics. Technology, Consumer Testing and Partnerships The company said its consumer business continued to grow at a double-digit rate, supported by demand for consumer-initiated testing and digital tools. Labcorp plans to launch its Marker by Labcorp genetic health offering through Labcorp OnDemand in August, combining biomarker and genetic testing options for consumers.

Schechter said the company is focused on its own consumer-testing platform while remaining selective about partnerships, citing the importance of maintaining a favorable margin profile. Labcorp OnDemand includes more than 200 biomarkers, he said, with offerings across cancer screening, men’s and women’s health, allergies and wellness.

Labcorp also expanded its collaboration with Epic, making more than 6,500 Labcorp diagnostic tests available through Epic’s Aura platform. The company completed acquisitions of select outreach laboratory services from Parkview Health in Indiana and Ohio, as well as Tribal Diagnostics, which serves communities in Oklahoma and Texas.

Looking ahead, Schechter said Labcorp’s pipeline for hospital and laboratory partnership transactions remains strong. He said the company requires acquisitions to be accretive in the first year and to return their cost of capital within two to three years.

About Labcorp (NYSE:LH)Laboratory Corporation of America Holdings, commonly known as Labcorp NYSE: LH, is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp's core businesses encompass clinical laboratory testing and pharmaceutical development services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Labcorp Right Now?Before you consider Labcorp, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Labcorp wasn't on the list.

While Labcorp currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Key Takeaways Labcorp beat Q2 earnings and revenue estimates, while shares fell nearly 6% in pre-market trading.LH expanded gross and adjusted operating margins on organic growth and operating efficiencies.Labcorp raised 2026 revenue and adjusted earnings guidance while maintaining free cash flow outlook. Labcorp Holdings Inc. (LH - Free Report) reported second-quarter 2026 adjusted earnings of $4.99 per share, up 14.9% year over year. The metric beat the Zacks Consensus Estimate by 4.18%.

On a GAAP basis, earnings per share (EPS) came in at $3.64, up 28.5% from the prior-year quarter. Net earnings attributable to Labcorp rose to $298.7 million from $237.9 million.

Revenues rose 5.8% to $3.73 billion and surpassed the Zacks Consensus Estimate by 0.36%. Enterprise revenues increased on 4.2% organic growth, a 1.2% contribution from acquisitions net of divestitures and a 0.4% foreign currency benefit. The mix indicates that underlying business activity accounted for most of the top-line expansion.

Following the announcement, Labcorp shares dipped 5.6% in the pre-market session today. 

LH Reports Broad-Based Revenue GrowthDiagnostics Laboratories (Dx) revenues rose 5.5% to $2.90 billion. Organic growth was 3.6%, while acquisitions net of divestitures added 1.9%. Total requisition volume increased 3%, including 1.8% organic growth and a 1.3% acquisition contribution. Price and mix improved 2.5%, with organic price and mix up 1.8%.

Biopharma Laboratory Services (BLS) revenues advanced 6.5% to $836.2 million. Organic growth was 6.2%, and foreign exchange added 1.8%, partly offset by a 1.4% reduction from acquisitions net of divestitures. Central Labs revenues climbed 9.8%, while Early Development revenues declined 1.4%.

Labcorp’s Margins ExpandGross profit increased to $1.11 billion from $1.05 billion a year earlier. Gross margin was 29.8%, up roughly 10 basis points (bps) from the prior-year quarter, as revenue growth outpaced the increase in the cost of revenues.

Adjusted operating income increased to $588.7 million from $531.6 million. The adjusted operating margin widened 70 bps to 15.8%, reflecting organic growth and operating efficiencies.

Reported operating income was $451.6 million compared with $394.5 million. The reported operating margin improved 90 bps to 12.1%, while selling, general and administrative expenses declined to $577.2 million from $579.3 million.

Labcorp’s Cash PositionLabcorp exited the second quarter of 2026 with cash and cash equivalents of $141.8 million compared with $981.1 million at the end of the first quarter. Debt totaled $5.86 billion at quarter-end. 

Cumulative net cash provided by operating activities at the end of the second quarter was $637 million compared with $639.1 million a year ago.

LH Deploys Capital Across PrioritiesLabcorp invested $225.7 million in acquisitions, repurchased $353.8 million of stock and paid $58.7 million in dividends during the quarter. It also retired $500 million of senior notes. The board increased the share repurchase authorization by $1 billion, bringing the remaining authorization to $1.4 billion.

Labcorp Updates 2026 OutlookManagement raised full-year enterprise revenue growth guidance to 5.4-6.3% from 5-6.1%. The updated range implies revenues of $14.71-$14.83 billion. Dx growth is now projected at 5.3-6%, while BLS growth is expected at 5.5-6.5%. The Zacks Consensus Estimate for full-year revenues is pegged at $14.71 billion, implying growth of 5.4%. 

Adjusted earnings guidance increased to $18.10-$18.55 per share, from the earlier $17.70-$18.35 range. The Zacks Consensus Estimate for the metric is pegged at $18.00.

Free cash flow guidance remained $1.24-$1.36 billion.

Our TakeLabcorp exited the second quarter of 2026 with both earnings and revenues beating estimates. Both segments contributed to the quarter's performance. The company expanded its capabilities in oncology and other high-growth specialty areas, strengthened its position as the partner of choice for health systems, biopharmaceutical companies and regional and local laboratories and advanced the use of technology to improve the experience for consumers and providers. Both gross and operating margins expanded during the quarter, which is highly encouraging.

LH’s Zacks Rank and Other Key PicksLabcorp currently carries a Zacks Rank #2 (Buy).

Some other top-ranked stocks from the broader medical space are Intuitive Surgical (ISRG - Free Report) , Quest Diagnostics (DGX - Free Report) and Medpace (MEDP - Free Report) .

Intuitive Surgical, carrying a Zacks Rank #2, reported second-quarter 2026 adjusted EPS of $2.80, which surpassed the Zacks Consensus Estimate by 12.9%. Revenues of $2.89 billion beat the Zacks Consensus Estimate by 3.1%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

ISRG has an earnings yield of 3.1% compared to the industry’s negative 3% yield. The company beat earnings estimates in each of the trailing four quarters, the average surprise being 16.53%.

Quest Diagnostics, carrying a Zacks Rank #2 at present, posted second-quarter 2026 adjusted EPS of $3.12, exceeding the Zacks Consensus Estimate by 11%. Revenues of $3.04 billion topped the Zacks Consensus Estimate by 2.1%.

DGX has an earnings yield of 4.7%, almost in line with the industry’s yield. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 5.77%.

Medpace, carrying a Zacks Rank #2 at present, posted second-quarter 2026 adjusted EPS of $4.25, exceeding the Zacks Consensus Estimate by 4.17%. Revenues of $707.3 million outperformed the consensus mark by 1.12%.

MEDP has an historical five-year earnings growth rate of 30.5% compared with the industry’s 5.6% growth. In the trailing four quarters, the company delivered an average earnings beat of 10.16%.

Results from operations for second quarter 2026 versus second quarter 2025: Revenue: $3.73 billion vs. $3.53 billion, up 5.8% Diluted EPS: $3.64 vs. $2.84, up 28.5% Adjusted EPS: $4.99 vs. $4.35, up 14.9% Raised full-year enterprise revenue growth and adjusted EPS guidance: Annual revenue growth guidance of 5.4% to 6.3%; up 30 basis points at the midpoint Adjusted EPS range of $18.10 to $18.55; up 30 cents at the midpoint Announced $1.0 billion increase in share repurchase authorization, bringing the remaining total authorization to $1.4 billion Advanced Labcorp Oncology offerings in lung, colorectal, and prostate cancers, expanding access to screening, improving diagnosis, guiding treatment selection, and monitoring recurrence Announced the launch of Marker by Labcorp™, a genetic health panel that provides consumers with personalized genetic insights , /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the second quarter ended June 30, 2026 and updated its full-year financial guidance.

"Labcorp delivered another very strong quarter, with 6% revenue growth, significant margin expansion, and double-digit adjusted EPS growth reflecting continued momentum across the business," said Adam Schechter, Chairman and CEO of Labcorp. "During the second quarter, we expanded our leadership in oncology and other high-growth specialty areas, strengthened our position as the partner of choice for health systems, biopharmaceutical companies, and regional/local laboratories, and advanced our use of technology to improve the experience for consumers and providers. Our performance and continued execution position us well to deliver sustainable growth and long-term value for customers and shareholders."

Labcorp continues to advance its strategic priorities:

Lead in specialty testing, with several advancements in Labcorp Oncology:

Added an advanced DPYD genotyping test that helps identify patients at risk for severe chemotherapy treatment-related toxicity. Launched ColoSense® nationwide, the first FDA-approved, RNA-based colorectal cancer screening test with at-home collection. With Medicare and expanding commercial payer coverage, this test increases patient access to screening and enables earlier detection. As ColoSense's primary nationwide distributor, we are further strengthening our comprehensive colorectal cancer portfolio. Entered into a clinical trial collaboration with Fox Chase Cancer Center to evaluate Labcorp's Plasma Detect Genome MRD in patients at risk of early-stage non-small cell lung cancer recurrence. Expanded nationwide access to Roche's FDA-approved VENTANA PTEN (SP218) companion diagnostic for people living with prostate cancer who may now be eligible for combination treatment with AstraZeneca's targeted therapy TRUQAP. Be a partner of choice for health systems and regional/local laboratories:

Awarded once again a Department of Defense contract to provide laboratory testing for service members and their families across military hospitals worldwide. Completed the acquisition of select outreach laboratory services from Parkview Health in Indiana and Ohio. Completed the acquisition of Tribal Diagnostics, a clinical laboratory serving communities in Oklahoma and Texas. Grow Consumer Health:

Announced the Marker by Labcorp Genetic Health Panel through Labcorp OnDemand where consumers can get their biomarker and genetic testing and insights from a single source.  Introduced Canada's first at-home, self-collection test to measure women's fertility-related hormones and men's testosterone levels. Launched an AI-powered app, MyLabcorp, which has been downloaded by millions of consumers. The app allows patients to schedule appointments, view their test results, and gain deeper insights into their health. Shape our future through technology and innovation:

Expanded a collaboration with Epic to place 6,500-plus diagnostic tests on Epic's Aura platform.  Enhanced the patient experience at Labcorp's Patient Service Centers, through expanded appointment availability, streamlined scheduling, and proactive rescheduling reminders and assistance. Labcorp also remains committed to a disciplined allocation of capital. In the second quarter of 2026, the company invested $225.7 million in acquisitions, repurchased $353.8 million of stock, and paid out $58.7 million in dividends. The company also paid down $500.0 million in senior notes in June. On July 9, 2026, the company announced a quarterly cash dividend of $0.72 per share of common stock, payable on September 11, 2026, to stockholders of record at the close of business on August 28, 2026. In July, the Board of Directors approved an increase of $1.0 billion in the company's share repurchase authorization, bringing the remaining total authorization to $1.4 billion.

LABCORP HOLDINGS INC. AND SUBSIDIARIES

CONSOLIDATED RESULTS

Three Months Ended June 30,

Six Months Ended June 30,

2026

2025

Delta

2026

2025

Delta

Revenue Summary (Dollars in millions)

Total Revenue

$ 3,731.1

$ 3,527.3

5.8 %

$ 7,268.7

$ 6,872.4

5.8 %

Organic(1)

4.2 %

3.6 %

Acquisitions, net of Divestitures(2)

1.2 %

1.3 %

Foreign Exchange

0.4 %

0.9 %

(1) Excludes the impact from acquisitions, divestitures, and currency, as well as other strategic actions taken in Early Development.

(2) Includes the impact from strategic actions taken in Early Development.

Earnings Summary (Dollars in millions, except per share data)

Operating Income ("OI")

$   451.6

$   394.5

$    832.4

$    720.5

OI as % of Revenue

12.1 %

11.2 %

90 bps

11.5 %

10.5 %

100 bps

Adjustments (3)

$   137.1

$   137.1

$    264.2

$    280.1

Adjusted Operating Income  ("AOI") (4)

$   588.7

(5)

$   531.6

$ 1,096.6

$ 1,000.6

AOI as % of Revenue

15.8 %

(5)

15.1 %

70 bps

15.1 %

14.6 %

50 bps

Net Earnings Attributable to Labcorp
Holdings Inc.

$   298.7

$   237.9

$   576.5

$   450.7

Diluted EPS

$     3.64

$     2.84

$     6.99

$     5.36

Adjusted EPS (4)

$     4.99

$     4.35

14.9 %

$     9.24

$     8.19

12.8 %

(3) Adjustments include amortization, impairment charges, restructuring charges, and special items.

(4) Non-GAAP financial measure. See "Reconciliation of Non-GAAP Measures" for additional information.

(5) The increase in adjusted operating income and margin was due to organic growth and operating efficiencies.

LABCORP HOLDINGS INC. AND SUBSIDIARIES

CONSOLIDATED RESULTS

Three Months Ended June 30,

Six Months Ended June 30,

2026

2025

2026

2025

Cash Flow Summary (Dollars in millions)

Operating Cash Flow

$        445.5

$        620.6

$         637.0

$         639.1

Capital Expenditures

131.6

77.9

252.6

203.9

Free Cash Flow

$        313.9

(1)

$        542.7

$         384.4

$         435.2

(1) The difference in free cash flow was primarily due to working capital timing and planned increases in capital expenditures.

Capital Allocation Summary

At the end of the quarter, Labcorp's cash and cash equivalents balance was $141.8 million and total debt was $5.86 billion.  In June, we retired $500.0 million in senior notes. During the quarter, the company invested $225.7 million in acquisitions, repurchased $353.8 million of stock, and paid out $58.7 million in dividends. LABCORP HOLDINGS INC. AND SUBSIDIARIES

Diagnostics Laboratories Segment Summary

Three Months Ended June 30,

2026

2025

Delta

Revenue Summary (Dollars in millions)

Total Revenue

$           2,900.7

$           2,748.8

5.5 %

Organic

3.6 %

Acquisitions, net of Divestitures

1.9 %

Earnings Summary (1) (Dollars in millions)

Adjusted Operating Income ("AOI") (2)

$ 522.6

(3)

$ 482.8

AOI as % of Revenue

18.0 %

(3)

17.6 %

50 bps

(1) Non-GAAP financial measure. See "Reconciliation of Non-GAAP Measures" for additional information.

(2) Excludes amortization, restructuring charges, special items, and unallocated corporate expenses.

(3) Adjusted Operating Income and margin increased due to organic growth and operating efficiencies.

Three Months Ended June 30, 2026

Requisition

Price/Mix

Volume Delta (4)

Delta (4)

Metrics Summary

Total

3.0 %

2.5 %

Organic (5)

1.8 %

1.8 %

Acquisitions, net of Divestitures

1.3 %

0.6 %

Foreign Exchange

— %

— %

(4) Column shows changes versus the three months ended June 30, 2025.

(5) Organic price/mix includes lab management agreements.

LABCORP HOLDINGS INC. AND SUBSIDIARIES

Biopharma Laboratory Services Segment Summary

Three Months Ended June 30,

2026

2025

Delta

Revenue Summary (Dollars in millions)

Total Revenue

$ 836.2

$ 784.8

6.5 %

(1)

Organic(2)

6.2 %

Acquisitions, net of Divestitures(3)

(1.4) %

Foreign Exchange

1.8 %

(1) Central Labs revenue growth of 9.8%; Early Development revenue was down 1.4%.

(2) Excludes the impact from acquisitions, divestitures, and currency, as well as other strategic actions taken in Early Development.

(3) Includes the impact from strategic actions taken in Early Development.

Earnings Summary (4) (Dollars in millions)

Adjusted Operating Income ("AOI") (5)

$ 142.2

(6)

$ 123.3

AOI as % of Revenue

17.0 %

(6)

15.7 %

130 bps

(4) Non-GAAP financial measure. See "Reconciliation of Non-GAAP Measures" for additional information.

(5) Excludes amortization, restructuring charges, special items, and unallocated corporate expenses.

(6) Adjusted Operating Income and margin increased, driven by organic growth and operating efficiencies from the strategic actions taken in Early Development.

As of

June 30, 2026

Metrics Summary (Dollars in billions)

TTM Net Orders

$           3.32

TTM Book to Bill

1.03

Backlog

$           8.73

(7)

Next Twelve Months Forecast Backlog Conversion

$           2.75

(7) Backlog increased 0.2% compared to this period last year.

Guidance for 2026

Labcorp is updating 2026 full year guidance to reflect its second quarter performance and full year outlook. The following guidance assumes foreign exchange rates effective as of June 30, 2026. Enterprise level guidance includes the estimated impact from currently anticipated capital allocation, including acquisitions, share repurchases, and dividends.

(Dollars in millions, except per share data)

Previous

Updated

2026 Guidance

2026 Guidance

Low

High

Low

High

Revenue

Labcorp Enterprise (1)(2)

$14,649

$14,803

$14,710

$14,827

Growth (3)

5.0 %

6.1 %

5.4 %

6.3 %

Diagnostics Laboratories

$11,431

$11,518

$11,450

$11,532

Growth (3)

5.1 %

5.9 %

5.3 %

6.0 %

Biopharma Laboratory Services (4)

$3,216

$3,266

$3,269

$3,300

Growth (3)

3.8 %

5.4 %

5.5 %

6.5 %

Adjusted EPS

$17.70

$18.35

$18.10

$18.55

Free Cash Flow

$1,240

$1,360

$1,240

$1,360

(1) 2026 Updated Enterprise guidance includes an impact from foreign currency translation of 0.4%.

(2) Enterprise level revenue is presented net of intercompany transaction eliminations.

(3) Growth based on 2025 Enterprise revenue of $13,952 million, Diagnostics Laboratories revenue of $10,876 million, and Biopharma Laboratory Services revenue of $3,098 million.

(4) 2026 Updated Biopharma Laboratory Services guidance includes an impact from foreign currency translation of 1.5%.

Use of Adjusted Measures
The company has provided in this press release and accompanying tables "adjusted" financial information that has not been prepared in accordance with GAAP, including adjusted net income, adjusted EPS (or adjusted net income per share), adjusted operating income, adjusted operating margin, free cash flow, and certain segment information. The company believes these adjusted measures are useful to investors as a supplement to, but not as a substitute for, GAAP measures, in evaluating the company's operational performance. The company further believes that the use of these non-GAAP financial measures provides an additional tool for investors in evaluating operating results and trends, and growth and shareholder returns, as well as in comparing the company's financial results with the financial results of other companies. However, the company notes that these adjusted measures may be different from and not directly comparable to the measures presented by other companies. Reconciliations of these non-GAAP measures to the most comparable GAAP measures and an identification of the components that comprise "special items" used for certain adjusted financial information are included in the tables accompanying this press release.

The company today is providing an investor relations presentation with additional information on its business and operations, which is available in the investor relations section of the company's website at https://ir.labcorp.com. Analysts and investors are directed to the website to review this supplemental information.

A webcast discussing Labcorp's quarterly results will be held today at 9:00 a.m. ET and is available by accessing the Labcorp investor relations website and navigating to the "Events" section. Alternatively, the live webcast can be accessed on this link. This webcast will be archived and accessible for one year.

About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025, and performed more than 750 million tests for patients around the world. Learn more at www.labcorp.com. 

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements with respect to (i) the estimated 2026 guidance and related assumptions, (ii) the impact of various factors on operating and financial results, including global economic and market conditions  on the company's businesses, operating results, cash flows and/or financial condition, (iii) future business  strategies, (iv) expected savings, synergies and other benefits to the company, customers or patients from acquisitions and other transactions and partnerships, and (v) opportunities for future growth.

Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the company's control, including without limitation: (i) the failure to receive tax-free treatment with respect to the spin-off of the company's former Clinical Development and Commercialization Services business for U.S. federal income purposes; (ii) the impact of spin-off related items; (iii) personnel costs and potential difficulties with employee relations and retention; (iv) the trading price of the company's stock, competitive actions and other unforeseen changes and general uncertainties in the marketplace; (v) the impact of changes to existing or adoption of new laws and regulations applicable to the company, including healthcare reform, or changes to the interpretation and application of such laws and regulations; (vi) customer purchasing decisions, including changes in payer regulations or policies; (vii) adverse actions of governmental and third-party payers; (viii) changes in testing guidelines or recommendations; (ix) the impact of global geopolitical events; (x) the effect of public opinion on the company's reputation; (xi) adverse results in material litigation matters; (xii) failure to maintain or develop customer relationships; (xiii) the company's ability to develop or acquire new products and adapt to technological changes; (xiv) failure of the company's information technology, systems, or data security; (xv) the impact of potential losses under repurchase agreements; (xvi) adverse weather conditions; (xvii) the number of revenue days in a financial period; (xviii) inflation; (xix) increased competition; and (xx) the effect of exchange rate fluctuations. These factors, in some cases, have affected and in the future (together with other factors) could affect the company's ability to implement the company's business strategy, and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of the forward-looking statements.

The company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the company's most recent Annual Report on Form 10-K and subsequent Forms 10-Q, including in each case under the heading RISK FACTORS, and in the company's other filings with the SEC. The information in this press release should be read in conjunction with a review of the company's filings with the SEC including the information in the company's most recent Annual Report on Form 10-K, and subsequent Forms 10-Q, under the heading "MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS".

- End of Text -
- Tables to Follow -

LABCORP HOLDINGS INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

(In Millions, Except Per Share Data)

Three Months Ended June 30,

Six Months Ended June 30,

2026

2025

2026

2025

Revenues

$       3,731.1

$       3,527.3

$       7,268.7

$       6,872.4

Cost of revenues

2,619.1

2,481.1

5,142.9

4,878.2

Gross profit

1,112.0

1,046.2

2,125.8

1,994.2

Selling, general, and administrative expenses

577.2

579.3

1,128.2

1,125.3

Amortization of intangibles and other assets

78.1

68.3

153.7

137.9

Restructuring and other charges

5.1

4.1

11.5

10.5

Operating income

451.6

394.5

832.4

720.5

Other (expense) income:

Interest expense

(61.1)

(57.1)

(116.2)

(113.1)

Investment income

5.6

1.7

17.8

8.2

Equity method loss, net

(6.2)

(1.7)

(11.3)

(2.0)

Other, net

(3.5)

(32.7)

(16.6)

(33.7)

Earnings from operations before income taxes

386.4

304.7

706.1

579.9

Provision for income taxes

87.3

66.4

129.0

128.6

Net earnings

299.1

238.3

577.1

451.3

Less: Net earnings attributable to the noncontrolling
interest

(0.4)

(0.4)

(0.6)

(0.6)

Net earnings attributable to Labcorp Holdings Inc.

$         298.7

$         237.9

$         576.5

$         450.7

Earnings per common share:

Basic earnings per common share

$          3.66

$          2.85

$          7.03

$          5.40

Diluted earnings per common share

$          3.64

$          2.84

$          6.99

$          5.36

Weighted-average basic common shares outstanding

81.7

83.4

82.0

83.5

Weighted-average diluted common shares outstanding

82.0

83.9

82.4

84.1

LABCORP HOLDINGS INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(In Millions)

June 30, 2026

December 31, 2025

ASSETS

Current assets:

Cash and cash equivalents

$               141.8

$               532.3

Accounts receivable, net

2,342.4

2,103.8

Unbilled services, net

162.4

156.9

Supplies inventory

562.2

534.7

Prepaid expenses and other

606.1

692.8

Total current assets

3,814.9

4,020.5

Property, plant, and equipment, net

3,100.5

3,081.5

Goodwill, net

7,030.1

6,789.5

Intangible assets, net

3,678.2

3,596.0

Joint venture partnerships and equity method investments

139.3

153.9

Other assets, net

769.3

751.3

Total assets

$           18,532.3

$           18,392.7

LIABILITIES AND SHAREHOLDERS' EQUITY

Current liabilities:

Accounts payable

$               688.5

$               840.8

Accrued expenses and other

862.4

847.8

Unearned revenue

387.8

439.1

Short-term operating lease liabilities

180.3

191.1

Short-term finance lease liabilities

4.7

4.6

Short-term borrowings and current portion of long-term debt

0.9

500.1

Total current liabilities

2,124.6

2,823.5

Long-term debt

5,857.6

5,084.6

Operating lease liabilities

661.0

682.6

Finance lease liabilities

61.6

63.0

Deferred income taxes and other tax liabilities

486.7

454.5

Other liabilities

717.6

647.8

Total liabilities

9,909.1

9,756.0

Commitments and contingent liabilities

Noncontrolling interest

16.4

16.9

Shareholders' equity:

Common stock, 80.9 and 82.2 shares outstanding at June 30, 2026, and
December 31, 2025, respectively

7.3

7.5

Additional paid-in capital

—

—

Retained earnings

8,701.4

8,639.9

Accumulated other comprehensive loss

(101.9)

(27.6)

Total shareholders' equity

8,606.8

8,619.8

Total liabilities and shareholders' equity

$           18,532.3

$           18,392.7

LABCORP HOLDINGS INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In Millions)

Three Months Ended June 30,

Six Months Ended June 30,

2026

2025

2026

2025

CASH FLOWS FROM OPERATING ACTIVITIES:

Net earnings

$   299.1

$   238.3

$   577.1

$   451.3

Adjustments to reconcile net earnings to net cash provided by operating activities:

Depreciation and amortization

179.0

170.3

352.3

337.1

Stock compensation

34.9

34.1

66.6

66.9

Operating lease right-of-use asset expense

49.1

50.8

97.1

99.4

Deferred income taxes

24.4

(6.1)

26.4

(12.2)

Other, net

14.2

38.0

25.6

46.1

Change in assets and liabilities (net of effects of acquisitions and divestitures):

(Increase) decrease in accounts receivable

(59.2)

30.9

(247.1)

(139.9)

(Increase) decrease in unbilled services

(0.7)

0.9

(6.9)

4.8

Increase in supplies inventory

(65.1)

(11.9)

(29.7)

(3.5)

Decrease in prepaid expenses and other

23.1

12.8

27.1

57.8

(Decrease) increase in accounts payable

(11.7)

67.0

(150.4)

(80.6)

(Decrease) increase in unearned revenue

(17.6)

0.2

(49.7)

(8.7)

Decrease in accrued expenses and other

(24.0)

(4.7)

(51.4)

(179.4)

Net cash provided by operating activities

445.5

620.6

637.0

639.1

CASH FLOWS FROM INVESTING ACTIVITIES:

Capital expenditures

(131.6)

(77.9)

(252.6)

(203.9)

Proceeds from sale of assets

1.9

1.9

9.7

2.4

Proceeds from sale or distribution of equity affiliates or other investments

—

6.9

—

6.9

Purchase of equity affiliates or other investments

(10.8)

(15.0)

(17.5)

(172.0)

Acquisition of businesses, net of cash acquired

(225.7)

(10.0)

(427.9)

(63.5)

Net cash used for investing activities

(366.2)

(94.1)

(688.3)

(430.1)

CASH FLOWS FROM FINANCING ACTIVITIES:

Proceeds from term loan

—

—

750.0

—

Payments on senior notes

(500.0)

—

(500.0)

(1,000.0)

Proceeds from accounts receivable securitization

175.0

—

175.0

225.0

Payments on accounts receivable securitization

(150.0)

—

(150.0)

—

Proceeds from revolving credit facilities

—

—

—

64.8

Payments on revolving credit facilities

—

—

—

(64.8)

Net share settlement tax payments from issuance of stock to employees

(6.3)

(3.5)

(46.1)

(29.0)

Net proceeds from issuance of stock to employees

1.8

—

34.7

25.7

Dividends paid

(58.7)

(59.9)

(119.9)

(121.5)

Purchase of common stock

(353.8)

(200.0)

(451.8)

(200.0)

Other, net

(27.9)

(4.0)

(31.3)

(7.3)

Net cash used for financing activities

(919.9)

(267.4)

(339.4)

(1,107.1)

Effect of exchange rate on changes in Cash and cash equivalents

1.3

18.8

0.2

26.7

Net (decrease) increase in Cash and cash equivalents

(839.3)

277.9

(390.5)

(871.4)

Cash and cash equivalents at beginning of period

981.1

369.4

532.3

1,518.7

Cash and cash equivalents at end of period

$   141.8

$   647.3

$   141.8

$   647.3

LABCORP HOLDINGS INC. AND SUBSIDIARIES

Condensed Combined Non-GAAP Segment Information

(Dollars in Millions)

Three Months Ended June 30,

Six Months Ended June 30,

2026

2025

2026

2025

Diagnostics Laboratories

Revenues

$    2,900.7

$    2,748.8

$     5,662.8

$     5,378.4

Adjusted operating income

$       522.6

$       482.8

$        981.3

$        910.3

Adjusted operating margin

18.0 %

17.6 %

17.3 %

16.9 %

Biopharma Laboratory Services

Revenues

$       836.2

$      784.8

$     1,616.8

$     1,506.1

Adjusted operating income

$       142.2

$      123.3

$        262.9

$        230.2

Adjusted operating margin

17.0 %

15.7 %

16.3 %

15.3 %

Consolidated

Revenues

$    3,731.1

$   3,527.3

$     7,268.7

$     6,872.4

Adjusted segment operating income

$       664.8

$      606.1

$     1,244.2

$     1,140.5

Unallocated corporate expense

(76.1)

(74.5)

(147.6)

(139.9)

Consolidated adjusted operating income

$      588.7

$      531.6

$     1,096.6

$     1,000.6

Adjusted operating margin

15.8 %

15.1 %

15.1 %

14.6 %

The consolidated revenue and adjusted segment operating income are presented net of intercompany transaction eliminations and other amounts not used in determining segment performance. Adjusted operating income and adjusted operating margin are non-GAAP measures. See the subsequent reconciliation of non-GAAP financial measures.

LABCORP HOLDINGS INC. AND SUBSIDIARIES

Reconciliation of Non-GAAP Measures

(Dollars and Shares in Millions, Except Per Share Data)

Three Months Ended June 30,

Six Months Ended June 30,

2026

2025

2026

2025

Adjusted Operating Income

Operating income

$      451.6

$      394.5

$       832.4

$       720.5

Amortization of intangibles and other assets (a)

78.1

68.3

153.7

137.9

Restructuring and other charges (b)

5.1

4.1

11.5

10.5

Acquisition and disposition-related costs (c)

21.3

15.1

31.2

44.2

LaunchPad costs (d)

11.7

17.2

24.7

37.3

Other

20.9

31.9

43.1

46.4

TSA reimbursement (e)

—

0.5

—

3.8

Adjusted operating income

$      588.7

$      531.6

$     1,096.6

$     1,000.6

Adjusted operating profit margin

15.8 %

15.1 %

15.1 %

14.6 %

Adjusted Net Income

Net income

$      298.7

$      237.9

$       576.5

$       450.7

Impact of adjustments to operating income

137.1

137.1

264.2

280.1

Loss on venture fund investments, net (f)

1.5

32.7

8.6

36.1

Equity method loss from SYNLAB investment (g)

6.2

—

11.2

—

TSA reimbursement (e)

—

(0.5)

—

(3.8)

Other

0.6

0.7

(7.9)

0.7

Income tax impact of adjustments (h)

(34.9)

(43.4)

(91.0)

(75.3)

Adjusted net income

$      409.2

$      364.5

$       761.6

$       688.5

Weighted-average diluted common shares outstanding

82.0

83.9

82.4

84.1

Adjusted net income per share

$       4.99

$       4.35

$         9.24

$         8.19

(a)

Amortization of intangible assets acquired as part of business acquisitions.

(b)

Restructuring and other charges represent amounts incurred in connection with the elimination of redundant positions and facilities and contract termination costs within the organization in connection with our LaunchPad initiatives, and acquisitions or dispositions of businesses by the company.

(c)

Acquisition and disposition-related costs include due-diligence legal and advisory fees, retention bonuses, impact of delayed contract or license transfers, and other integration or disposition related activities.

(d)

LaunchPad costs include non-capitalized costs associated with the implementation of systems, consolidation of processes, and consulting costs incurred as part of various business process improvement initiatives.

(e)

Represents transition services fees charged to Fortrea Holdings Inc. related to administrative and IT systems support.  The costs to provide these services are included in operating income but the service fees are included in other income.

(f)

The company makes investments in companies or investment funds developing promising technology related to its operations. The company recorded net gains and losses related to several distributions from venture funds, increases in the market value of investments, and impairments of other investments due to the underlying performance of the investments.

(g)

Adjustment removes the impact of the equity method income from the Company's minority investment in SYNLAB.

(h)

Income tax impact of adjustments calculated based on the tax rate applicable to each item.

SOURCE Labcorp Holdings Inc

Labcorp Holdings (LH - Free Report) came out with quarterly earnings of $4.99 per share, beating the Zacks Consensus Estimate of $4.79 per share. This compares to earnings of $4.35 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +4.18%. A quarter ago, it was expected that this medical laboratory operator would post earnings of $4.09 per share when it actually produced earnings of $4.25, delivering a surprise of +3.91%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

Labcorp, which belongs to the Zacks Medical Services industry, posted revenues of $3.73 billion for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 0.36%. This compares to year-ago revenues of $3.53 billion. The company has topped consensus revenue estimates two times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Labcorp shares have added about 22.4% since the beginning of the year versus the S&P 500's gain of 6.9%.

What's Next for Labcorp?While Labcorp has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Labcorp was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $4.59 on $3.76 billion in revenues for the coming quarter and $18.00 on $14.71 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical Services is currently in the top 31% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

One other stock from the same industry, Ardent Health, Inc. (ARDT - Free Report) , is yet to report results for the quarter ended June 2026. The results are expected to be released on August 4.

This company is expected to post quarterly earnings of $0.17 per share in its upcoming report, which represents a year-over-year change of -67.3%. The consensus EPS estimate for the quarter has been revised 2.1% higher over the last 30 days to the current level.

Ardent Health, Inc.'s revenues are expected to be $1.59 billion, down 3.3% from the year-ago quarter.

New offering analyzes 163 genes linked to more than 100 medically actionable conditions Includes genetic counseling support to help consumers understand results and take informed next steps Consumers can now access biomarker and hereditary genetic testing from a single source through Labcorp OnDemand , /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the launch of Marker by Labcorp™ Genetic Health Panel, a new offering designed to help consumers better understand inherited risks associated with more than 100 medically actionable health conditions. Available through Labcorp OnDemand, the panel analyzes 163 genes associated with hereditary cancer, cardiovascular conditions and metabolic conditions and includes access to licensed genetic counselors to help consumers understand their results and discuss appropriate next steps. The Marker by Labcorp Genetic Health Panel is backed by Labcorp's established expertise in clinical genetic testing through Labcorp Genetics and its Invitae genetic testing capabilities.

Photo courtesy of Labcorp Bridging Consumer Access and Clinical Genetics
Many people carry inherited genetic variants without knowing it. Research shows nearly one in six adults who undergo genetic testing discover a variant linked to a serious and medically actionable health condition. Family health history can provide important clues about inherited risk, but many people have incomplete or unavailable information about their relatives' health.

The Marker by Labcorp Genetic Health Panel was developed to help address this gap by combining clinical genetic testing, specimen collection and genetic counseling into a single consumer healthcare experience.

"Genetic information can play an important role in identifying health risks before symptoms appear, yet millions of people are unaware they carry an inherited genetic variant associated with an increased risk of serious disease," said Dr. Leslie Saltzman, vice president of consumer health solutions at Labcorp. "The Marker by Labcorp Genetic Health Panel expands access to genetic health insights by combining genetic testing, genetic counseling support and Labcorp's genetics expertise into a single, convenient healthcare experience. Consumers can now access both biomarker and genetic testing through Labcorp OnDemand from a single source, supporting a more comprehensive approach to understanding their health."

How the Testing Process Works
Consumers can purchase the Marker by Labcorp Genetic Health Panel directly through Labcorp OnDemand and schedule a blood draw at one of Labcorp's more than 2,200 patient service centers nationwide. Specimen collection is performed by a trained phlebotomist, after which samples are sent to Labcorp laboratories for analysis.

Results are delivered through Labcorp's secure patient portal and MyLabcorp™, the company's AI-powered mobile platform, where consumers can view their genetic health report alongside other available Labcorp test results. A comprehensive report includes any identified findings, educational resources tailored to individual results, and access to a licensed genetic counselor who can help interpret results, answer questions and discuss appropriate next steps.i Consumers may also share their results with healthcare providers to support further discussions or decisions about their care.

Marker by Labcorp expands the testing options available through Labcorp OnDemand, connecting consumers to both biomarker and hereditary genetic testing through a single trusted source.

The Marker by Labcorp Genetic Health Panel will be available through Labcorp OnDemand beginning August 3, 2026. To learn more, visit https://www.ondemand.labcorp.com/.

About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests for patients around the world. Learn more at www.labcorp.com.

i Results are not diagnostic and should be considered together with a person's medical history, family history and other risk factors.

SOURCE Labcorp

Labcorp (LH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Key Takeaways Labcorp is expected to post Q2 revenue growth of 5.4% and EPS growth of 10.1% year over year.LH expanded diagnostics through partnerships, acquisitions and new oncology, neurology and consumer tests.Labcorp likely saw BLS support from Central Laboratories as Early Development streamlining continued. Labcorp Holdings Inc. (LH - Free Report) , or Labcorp, is slated to report its second-quarter 2026 results on July 30, before the market opens.

In the last reported quarter, the company posted adjusted earnings per share (EPS) of $4.25, surpassing the Zacks Consensus Estimate by 3.91%. Labcorp outpaced estimates in each of the trailing four quarters, the average surprise being 3.31%.

Q2 Estimates for LHThe Zacks Consensus Estimate for Labcorp’s second-quarter 2026 revenues is pegged at $3.72 billion. This suggests a 5.4% rise from the year-ago reported figure.

The Zacks Consensus Estimate for second-quarter EPS indicates an improvement of 10.1% to $4.79. The estimate has remained unchanged in the past 60 days.

Here's a quick review of the company’s performance leading up to its second-quarter earnings.

What Could Shape Labcorp's Q2 Results?In the second quarter of 2026, Diagnostics Laboratories’ (Dx) performance is likely to have continued to witness strong organic contribution. Labcorp's ongoing expansion through health system partnerships and acquisitions is expected to have supported testing volumes by broadening its patient and provider network. During the quarter, the company announced a nationwide strategic collaboration with Children's Hospital of Philadelphia to expand access to advanced diagnostics for pediatric patients.

In May, Labcorp launched an expanded DPYD Genotyping test to identify cancer patients at risk for severe chemotherapy side effects. Earlier in March, it acquired the select assets of Crouse Health's Laboratory Alliance of Central New York and executed an agreement to manage Crouse Health’s inpatient laboratories. All these developments are expected to have favorably boosted the quarter’s top line.

The company’s expanding specialty testing portfolio likely remained another tailwind. These tests are focused in the areas spanning oncology, women's health, neurology and autoimmune disease, which are projected to far outpace the broader diagnostics market. In second-quarter 2026, Oncology results are likely to have benefited from the launch of several liquid biopsy tests and expanded access to molecular residual disease (MRD) solutions.

Labcorp further strengthened the portfolio by launching Agilent Technologies' FDA-approved companion diagnostic to identify patients with platinum-resistant ovarian cancer who may be eligible for Merck's KEYTRUDA. The company’s market-leading Alzheimer's testing portfolio may have boosted Neurology revenues.

Beyond the core testing, the company also introduced the first FDA-cleared rapid fentanyl test of its kind made in the United States, delivering results in just 10 minutes. The Labcorp OnDemand platform is also expected to have favorably supported revenues, driven by strong demand across its expanding menu of consumer health tests.

Labcorp may have also benefited from its ongoing use of advanced technologies, including AI and robotics, to enhance customer experiences and productivity. In April, the company expanded its collaboration with Epic, making its full test menu available through the Aura platform. Other recent initiatives include the development of an AI-powered real-world data platform with Amazon Web Services and Datavant to accelerate Alzheimer's research and a strategic collaboration with Optum.ai to streamline laboratory operations. Collectively, all these factors are expected to have positively impacted Labcorp’s second-quarter revenues.

The Zacks Consensus Estimate expects Dx revenues to grow 6.1% year over year.

Within the Biopharma Laboratory Services (“BLS”) segment,Labcorp has likely benefited from the solid performance of Central Laboratories. The company may have also progressed with its strategic actions to streamline the Early Development business, which may have limited overall growth. 

The Zacks Consensus Estimate suggests that BLS revenues will grow 2.7% year over year.

Earnings Whispers for LabcorpPer our proven model, stocks with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, have a higher chance of beating estimates, which is exactly the case here, as you can see below:

Earnings ESP:  Labcorp has an Earnings ESP of +0.71%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

Zacks Rank: The company currently carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.

Other Key MedTech PicksHere are some other medical stocks worth considering, as these also have the right combination of elements to post an earnings beat this time:

CVS Health (CVS - Free Report) has an Earnings ESP of +1.42% and a Zacks Rank #2. The company is slated to release second-quarter 2026 results on Aug. 5.

CVS’ earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.79%. The Zacks Consensus Estimate expects the company’s second-quarter EPS to increase 3.3% from the year-ago quarter’s figure.

Henry Schein (HSIC - Free Report) has an Earnings ESP of +0.41% and a Zacks Rank #2. The company is expected to release second-quarter 2026 results soon.

HSIC’s earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 3.74%. The Zacks Consensus Estimate for the company’s second-quarter EPS calls for a rise of 10.9% from the year-ago quarter’s figure.

Alcon (ALC - Free Report) has an Earnings ESP of +3.13% and a Zacks Rank #2. The company is slated to release second-quarter 2026 results on Aug. 10.

ALC’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 3.66%. The Zacks Consensus Estimate anticipates the company’s second-quarter EPS to increase 1.3% from the year-ago quarter’s figure.

Posted by Defense World Staff on Jul 21st, 2026

California Public Employees Retirement System decreased its position in Labcorp Holdings Inc. (NYSE:LH – Free Report) by 8.6% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 195,176 shares of the medical research company’s stock after selling 18,270 shares during the quarter. California Public Employees Retirement System owned 0.24% of Labcorp worth $52,075,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in LH. Vanguard Group Inc. increased its holdings in shares of Labcorp by 0.4% during the fourth quarter. Vanguard Group Inc. now owns 9,850,631 shares of the medical research company’s stock worth $2,471,326,000 after buying an additional 37,197 shares in the last quarter. Victory Capital Management Inc. boosted its holdings in shares of Labcorp by 103.1% in the 4th quarter. Victory Capital Management Inc. now owns 5,356,825 shares of the medical research company’s stock worth $1,343,922,000 after acquiring an additional 2,719,475 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its holdings in shares of Labcorp by 1.0% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 2,226,446 shares of the medical research company’s stock worth $607,241,000 after acquiring an additional 22,170 shares in the last quarter. Geode Capital Management LLC grew its position in Labcorp by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 2,137,010 shares of the medical research company’s stock worth $534,023,000 after acquiring an additional 13,775 shares during the last quarter. Finally, Wellington Management Group LLP grew its position in Labcorp by 15.9% during the 3rd quarter. Wellington Management Group LLP now owns 2,105,791 shares of the medical research company’s stock worth $604,488,000 after acquiring an additional 289,029 shares during the last quarter. 95.94% of the stock is owned by institutional investors.

Labcorp Trading Down 0.9% Shares of LH opened at $280.86 on Tuesday. The company has a quick ratio of 1.54, a current ratio of 1.73 and a debt-to-equity ratio of 0.68. Labcorp Holdings Inc. has a 12-month low of $241.81 and a 12-month high of $293.72. The firm has a market capitalization of $23.03 billion, a PE ratio of 24.88, a price-to-earnings-growth ratio of 1.88 and a beta of 0.89. The stock’s fifty day simple moving average is $266.74 and its 200-day simple moving average is $268.21.

Labcorp (NYSE:LH – Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The medical research company reported $4.25 EPS for the quarter, topping analysts’ consensus estimates of $4.09 by $0.16. The firm had revenue of $3.54 billion during the quarter, compared to analyst estimates of $3.51 billion. Labcorp had a return on equity of 16.29% and a net margin of 6.66%.The company’s revenue was up 5.8% on a year-over-year basis. During the same period last year, the company earned $3.84 earnings per share. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. As a group, research analysts predict that Labcorp Holdings Inc. will post 18 earnings per share for the current year.

Labcorp Announces Dividend The firm also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 28th will be given a dividend of $0.72 per share. The ex-dividend date is Friday, August 28th. This represents a $2.88 annualized dividend and a dividend yield of 1.0%. Labcorp’s payout ratio is currently 25.51%.

Insider Transactions at Labcorp In related news, EVP Bryan T. Vaughn sold 234 shares of the business’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $286.19, for a total transaction of $66,968.46. Following the completion of the sale, the executive vice president directly owned 6,746 shares of the company’s stock, valued at $1,930,637.74. The trade was a 3.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Adam H. Schechter sold 5,903 shares of the stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $254.50, for a total transaction of $1,502,313.50. Following the completion of the transaction, the chief executive officer owned 107,234 shares in the company, valued at $27,291,053. This represents a 5.22% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 6,991 shares of company stock worth $1,796,696 in the last quarter. 0.84% of the stock is owned by company insiders.

Analyst Ratings Changes LH has been the subject of several research analyst reports. Weiss Ratings reiterated a “buy (b-)” rating on shares of Labcorp in a research report on Friday, May 8th. Evercore restated an “outperform” rating and issued a $300.00 target price on shares of Labcorp in a research note on Wednesday, April 8th. Bank of America lifted their price target on Labcorp from $300.00 to $320.00 and gave the company a “buy” rating in a report on Monday, July 13th. Wall Street Zen upgraded shares of Labcorp from a “hold” rating to a “buy” rating in a research report on Sunday, July 12th. Finally, Robert W. Baird increased their price objective on shares of Labcorp from $335.00 to $338.00 and gave the stock an “outperform” rating in a report on Monday, July 13th. Nine investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $314.40.

Check Out Our Latest Analysis on LH

About Labcorp (Free Report)

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.

Featured Stories Five stocks we like better than Labcorp The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story

Receive News & Ratings for Labcorp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Labcorp and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEFifth Third Bancorp Buys New Stake in Morgan Stanley Pathway Large Cap Equity ETF $MSLC

NEXT HEADLINE »Bessemer Group Inc. Purchases 36,940 Shares of CONMED Corporation $CNMD

HomeEarnings AnalysisHealthcare 

SummaryLabcorp remains a buy consideration, leveraging a successful rollup strategy in a fragmented laboratory testing industry for steady, predictable growth.Automation is driving cost reductions in LH’s operations. That cost reduction helps offset healthcare pricing pressures.With a larger scale, LH now targets single-digit growth and a total return around 10%, prioritizing predictability over rapid expansion.Risks are low due to recurring revenue, minimal acquisition disruption, and the sector’s resilience.This is probably one of the more predictable businesses that I follow.This idea was discussed in more depth with members of my private investing community, Oil & Gas Value Research. Learn More » JHVEPhoto/iStock Editorial via Getty Images

The last article that I wrote on Labcorp (LH) mentioned the fact that this company was basically set up as a "rollup corporation". It was going to grow by acquiring smaller "mom and pop" sized operations

25.85K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in LH over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Disclaimer: I am not a registered investment advisor and this article reflects my own opinions. I do not and will not advise anyone to invest or not invest in this stock. You have to do your own due diligence and your own homework, by reading the company's filings and press releases, as well as any other relevant information to make up your own mind at your own risk. Your investments must match your own risk profile as well as your desire to take on risk and the patience to see out situations such as this.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact , /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on September 11, 2026, to stockholders of record as of the close of business on August 28, 2026.

About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025, and performed more than 750 million tests for patients around the world. Learn more at www.labcorp.com.

SOURCE Labcorp Holdings Inc

Also from this source

Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact , /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the second quarter of 2026 before the market opens on Thursday, July 30, 2026. The company will host a webcast beginning at 9:00 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the "News & Events" section of the Labcorp Investor Relations website at https://ir.labcorp.com. A link to the earnings webcast will also be available on the investor relations website.

A replay of the webcast will be available on the "News & Events" section of the investor relations website after the conclusion of the live event and will be available for one year.

About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025, and performed more than 750 million tests for patients around the world. Learn more at https://www.labcorp.com/.

SOURCE Labcorp Holdings Inc

Also from this source

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.

Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.

Zacks Premium includes access to the Zacks Style Scores as well.

What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.

Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.

Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.

Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.

VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.

How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.

#1 (Strong Buy) stocks have produced an unmatched +24% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.

This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.

That's where the Style Scores come in.

You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only has a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.

The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.

Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Labcorp Holdings (LH - Free Report) Headquartered in Burlington, NC, Labcorp Holdings, Inc. or Labcorp, is a leading healthcare diagnostics company, providing comprehensive clinical laboratory services and end-to-end drug development support. In 2015, Labcorp acquired NJ based Covance, a drug development services company providing a wide range of early stage and late-stage product development services on a worldwide basis primarily to the pharmaceutical and biotechnology industries.

LH is a #2 (Buy) on the Zacks Rank, with a VGM Score of A.

It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 14.73; value investors should take notice.

Nine analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.39 to $18.00 per share. LH also boasts an average earnings surprise of +3.3%.

With a solid Zacks Rank and top-tier Value and VGM Style Scores, LH should be on investors' short list.

Investors looking for stocks in the Medical Services sector might want to consider either Labcorp Holdings (LH - Free Report) or Charles River Laboratories (CRL - Free Report) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.

The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision trends, while our Style Scores work to grade companies based on specific traits.

Right now, Labcorp Holdings is sporting a Zacks Rank of #2 (Buy), while Charles River Laboratories has a Zacks Rank of #3 (Hold). Investors should feel comfortable knowing that LH likely has seen a stronger improvement to its earnings outlook than CRL has recently. But this is only part of the picture for value investors.

Value investors also tend to look at a number of traditional, tried-and-true figures to help them find stocks that they believe are undervalued at their current share price levels.

The Value category of the Style Scores system identifies undervalued companies by looking at a number of key metrics. These include the long-favored P/E ratio, P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that help us determine a company's fair value.

LH currently has a forward P/E ratio of 14.78, while CRL has a forward P/E of 16.99. We also note that LH has a PEG ratio of 1.86. This popular figure is similar to the widely-used P/E ratio, but the PEG ratio also considers a company's expected EPS growth rate. CRL currently has a PEG ratio of 2.14.

Another notable valuation metric for LH is its P/B ratio of 2.51. Investors use the P/B ratio to look at a stock's market value versus its book value, which is defined as total assets minus total liabilities. By comparison, CRL has a P/B of 3.07.

These metrics, and several others, help LH earn a Value grade of B, while CRL has been given a Value grade of C.

LH stands above CRL thanks to its solid earnings outlook, and based on these valuation figures, we also feel that LH is the superior value option right now.

Labcorp Holdings (NYSE:LH) shares are up, up 1.46%, on Thursday as the company reported strong first-quarter results and raised its full-year guidance.

The stock’s positive movement follows an announcement that the company is committed to a disciplined allocation of capital, including significant investments in acquisitions and stock repurchases.

• Labcorp Holdings stock is showing upward movement. Why is LH stock trading higher?

Labcorp Q1 Results BeatLabCorp reported quarterly adjusted earnings of $4.25 per share, beating the consensus of $4.09. Sales jumped 5.8% to $3.54 billion, surpassing the consensus of $3.51 billion.

Technology Investments Drive Operational Momentum“Labcorp delivered another quarter of strong results, with robust growth and double-digit Adjusted EPS growth driven by continued momentum across our Diagnostics and Central Laboratory businesses,” said Adam Schechter, chairman and CEO of Labcorp.

“Our investments in advanced technologies, including robotics and AI, are improving the customer experience and transforming the way we operate. Driven by continued progress across our strategic priorities, we are raising our full-year Adjusted EPS guidance to $18.03 at the midpoint of the range, an increase of $0.13,” Schechter added on Thursday.

Guidance Raised Across Earnings and RevenueLabcorp raised fiscal 2026 adjusted earnings guidance from $17.55-$18.25 per share to $17.70-$18.35, compared to the consensus of $17.87.

The laboratory services provider increased 2026 sales guidance from $14.61 billion-$14.79 billion to $14.65 billion-$14.80 billion compared to the consensus of $14.66 billion.

LH Technical Outlook: Key Support, Resistance and MomentumLabcorp is currently trading within its 52-week range, positioned at $263.64, which is approximately 10% below its 52-week high of $293.72.

The stock is trading 1.5% below its 20-day simple moving average (SMA) and 2.7% below its 50-day SMA, suggesting a slight short-term bearish trend.

The 100-day SMA is also above the current price, indicating that the stock has struggled to maintain upward momentum recently.

The relative strength index (RSI) is at 37.57, suggesting neutral momentum, while the moving average convergence divergence (MACD) is below the signal line, indicating bearish pressure.

Key Resistance: $280 — This level may act as a barrier for upward movement. Key Support: $260.50 — A drop below this level could signal further weakness. How Labcorp Ranks On Value and Quality MetricsBelow is the Benzinga Edge scorecard for Labcorp Holdings, highlighting its strengths and weaknesses compared to the broader market:

Value: 31.93 — The stock is trading at a moderate valuation relative to peers. Quality: 65.19 — Indicates a solid balance sheet and operational efficiency. The Verdict: Labcorp Holdings’s Benzinga Edge signal reveals a balanced scorecard, with strong quality metrics but moderate value positioning. This suggests the company is well-managed but may face challenges in terms of valuation relative to growth prospects.

LH Stock Price Activity: Labcorp shares were up 1.46% at $261.10 at the time of publication on Thursday, according to Benzinga Pro data.

Photo via Shutterstock

This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

Key Takeaways Labcorp reported Q1 EPS of $4.25 and revenues of $3.54B, both beating estimates and rising year over year. LH saw growth across Diagnostics and Biopharma segments, driven by organic gains, volumes and FX tailwinds. Labcorp raised 2026 revenue and EPS guidance following strong results and ongoing strategic initiatives. Labcorp Holdings (LH - Free Report) or Labcorp reported first-quarter 2026 adjusted earnings per share (EPS) of $4.25, which beat the Zacks Consensus Estimate by 3.8%. The figure rose 10.6% from the year-ago level.

The adjusted figure excludes the impact of certain amortization expenses and restructuring charges, among others. 

On a GAAP basis, EPS was $3.35 compared with $2.52 in the year-ago period.

LH RevenuesFirst-quarter revenues rose 5.8% year over year to $3.54 billion. The figure surpassed the Zacks Consensus Estimate by 1%. 

The year-over-year increase was driven by organic revenue growth of 3.1%, acquisitions (net of divestitures) of 1.4% and a foreign currency translation gain of 1.3%.

Following the announcement, Labcorp’s shares edged up 0.7% in the pre-market session today. 

Labcorp’s Q1 Performance by SegmentsThe company currently operates under two segments — Diagnostics Laboratories and Biopharma Laboratory Services (comprised of its Central Laboratories and Early Development Research Laboratories).

Diagnostics Laboratories reported revenues of $2.76 billion, reflecting a 5% improvement year over year.

On an organic basis, revenues were up 2.9%. The company’s total volumes (measured by requisitions) increased 2.5%, as acquisition volumes contributed 1.4% and organic volumes rose 1.1%.

Biopharma Laboratory Services revenues rose 8.2% to $780.6 million in the quarter. The year-over-year increase was primarily driven by organic growth of 3.7% and a foreign currency translation gain of 5.5%.

Labcorp’s Margin PerformanceThe gross margin expanded 32 basis points (bps) to 28.7% in the first quarter despite a 5.3% rise in the cost of revenues.

The adjusted operating income improved 15.1% year over year to $462.8 million. The adjusted operating margin expanded 106 bps year over year to 13.1% despite 0.9% rise in SG&A expenses ($551 million).

Labcorp’s Cash PositionLabcorp exited the first quarter of 2026 with cash and cash equivalents of $981.1 million compared with $532.3 million at the end of the fourth quarter of 2025. Long-term debt totaled $5.83 billion in the quarter. 

Cumulative net cash provided by operating activities at the end of the first quarter was $191.5 million compared with $18.5 million a year ago.

Labcorp Holdings Inc. Price, Consensus and EPS SurpriseLH’s 2026 GuidanceLabcorp raised full-year 2026 enterprise revenue and adjusted EPS guidance. Enterprise-level guidance includes the estimated impact from currently anticipated capital allocation, including acquisitions, share repurchases and dividends.

Total revenues for 2026 are now expected to be in the range of $14.65-$14.80 billion (up from $14.61-$14.79 billion), representing growth of 5-6.1% (up from 4.7-6%). The Zacks Consensus Estimate for full-year revenues is pegged at $14.67 billion, representing growth of 5.2%. 

Labcorp now expects 2026 adjusted EPS to be in the band of $17.70-$18.35 (up from $17.55-$18.25). The Zacks Consensus Estimate for the metric is pegged at $17.67.

Our View on LH StockLabcorp exited the first quarter of 2026 with better-than-expected results, with both earnings and revenues beating estimates. All the business segments reported growth in the quarter.

Key growth drivers include the launch of an AI-powered real-world data platform with Amazon Web Services and Datavant to advance Alzheimer’s research, alongside the FDA-cleared Labcorp Fentanyl Visual Urine Test for rapid screening. During the first quarter, collaborations with PathAI enable the deployment of AISight, while work with Illumina expands access to advanced oncology genomic testing, improving precision in biomarker insights. Supported by the strong quarterly performance and multiple catalysts, management raised its 2026 outlook.

Meanwhile, expansion of both margins is encouraging.

LH’s Zacks Rank & Key PicksLabcorp currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , Intuitive Surgical (ISRG - Free Report) and Phibro Animal Health (PAHC - Free Report) .

Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a fourth-quarter 2025 adjusted EPS of $1.28, which surpassed the Zacks Consensus Estimate by 20.8%. Revenues of $826.4 million beat the Zacks Consensus Estimate by 4.9%. You can see the complete list of today’s Zacks #1 Rank stocks here.

GMED has an earnings yield of 4.7% compared with the industry’s negative yield of 1.4%. The company’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 18.79%.

Intuitive Surgical, carrying a Zacks Rank #2 (Buy) at present, posted a first-quarter 2026 adjusted EPS of $2.50, exceeding the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion topped the Zacks Consensus Estimate by 6.2%.

ISRG has an earnings yield of 2.1% in contrast to the industry’s negative yield of 0.9%. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 16.82%.

Phibro Animal Health, carrying a Zacks Rank #2 at present, posted a second-quarter fiscal 2026 adjusted EPS of 87 cents, exceeding the Zacks Consensus Estimate by 27.01%. Revenues of $373.9 million outperformed the Zacks Consensus Estimate by 4.72%.

PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12.1% growth. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 20.15%.

Labcorp's full test menu will be available through Epic's Aura platform Integration builds on the successful deployment of Invitae genetic testing and accelerates access to the latest genetic and specialty diagnostics through Aura Collaboration will help reduce IT complexity, streamline lab ordering and improve access to diagnostic innovation for hospitals and health systems using Epic nationwide , /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded collaboration with Epic, the nation's leading electronic health record (EHR) supporting hospitals and health systems. Through the collaboration, Labcorp's full test menu will be available through Aura, Epic's unified platform for ordering and receiving lab results. The integration will drive meaningful operational efficiencies, streamline lab ordering for clinicians and care teams, and improve access to diagnostic innovation for hospitals and health systems using Epic nationwide.

Reducing Complexity and Expanding Access to Testing and Diagnostic Innovation
Health systems often face lengthy, complex and time-consuming IT projects to integrate with laboratory partners. By leveraging Epic's Aura, the expansion will reduce the time, cost and ongoing maintenance typically required for lab interfaces. Building on the availability of Invitae genetic tests through Aura, part of Labcorp's diagnostic portfolio, health systems will be able to access Labcorp's full test menu and new tests as they are introduced directly within their existing Epic workflows.

"This expanded collaboration reflects how Labcorp is investing to meet the evolving needs of hospitals and health systems," said Bryan Vaughn, Executive Vice President and President of Diagnostics at Labcorp. "By simplifying lab integrations and delivering our full test menu directly within Epic workflows, we are expanding access and building a strong foundation for continued innovation."

Benefits for Clinicians and Health Systems
The expanded integration will deliver meaningful benefits including:

Simplified onboarding and maintenance – Aura's connectivity and content‑management capabilities reduce the effort required to onboard and maintain Labcorp's test menu, reducing integration complexity for hospitals and health systems. Seamless access within Epic workflows – Clinicians will be able to order Labcorp tests and receive discrete results directly within their Epic workflow, improving efficiency and reducing reliance on manual processes or workarounds. Broader access to Labcorp's full and evolving test menu, including new and advanced diagnostics. "Expanding Labcorp's use of Aura to include its full test menu makes it easy for clinicians to order the right test the first time, right from their workflow, so patients get accurate answers faster," said Sumit Rana, President of Epic.

To learn more about Labcorp's ongoing collaboration with Epic and future plans to advance diagnostic integration for hospitals and health systems, visit https://www.labcorp.com/organizations/epic. 

About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests for patients around the world. Learn more at www.labcorp.com.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements with respect to the expected utility and benefits of integrating Labcorp's full test menu into the Epic Aura platform.

Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the company's control. These factors, in some cases, have affected and in the future (together with other factors) could affect the company's ability to implement the company's business strategy, and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of the forward-looking statements.

The company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the company's most recent Annual Report on Form 10-K under the heading RISK FACTORS and in the company's other filings with the SEC. The information in this press release should be read in conjunction with a review of the company's filings with the SEC including the information in the company's most recent Annual Report on Form 10-K under the heading "MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS."

SOURCE Labcorp